Platinum-based therapy is considered the standard treatment for patients with advanced ovarian cancer. Carboplatin has a more favorable toxicity profile than cisplatin; however, hypersensitivity reactions to carboplatin have been reported occasionally. We reviewed 112 cases of ovarian cancer treated with carboplatin at our institute to identify the hypersensitivity reactions to this chemotherapeutic agent. Hypersensitivity reactions were documented in nine cases (8%). No deaths occurred, but the reactions were judged severe in three of the 112 patients (2.6%). In our own experience with patients showing idiosyncrasy to carboplatin we observed successful resolution after retreatment with cisplatin. Since patients who relapse after initial treatment with carboplatin often respond to it a second time, it is important to continue this treatment.
|Titolo:||Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases|
|Data di pubblicazione:||2003|
|Citazione:||Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases / Libra M; Sorio R; Buonadonna A; Berretta M; Stefanovski P; Toffoli G; Mazzaglia G; Cordani N; Stivala F; Boiocchi M. - In: TUMORI. - ISSN 0300-8916. - 89:3(2003), pp. 311-313.|
|Appare nelle tipologie:||1.1 Articolo in rivista|